Ono Pharmaceutical Co., Ltd.
OPHLF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $59,328,000 | $127,977,000 | $143,532,000 | $105,025,000 |
| Dep. & Amort. | $26,894,000 | $18,140,000 | $17,451,000 | $17,721,000 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $0 | $0 | $0 | $0 |
| Change in WC | $38,337,000 | -$28,958,000 | $1,437,000 | -$30,107,000 |
| Other Non-Cash | -$42,100,000 | -$6,499,000 | -$2,810,000 | -$30,810,000 |
| Operating Cash Flow | $82,459,000 | $110,660,000 | $159,610,000 | $61,829,000 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$5,431,000 | -$4,020,000 | -$14,497,000 | -$12,277,000 |
| Net Acquisitions | -$364,816,000 | $0 | -$9,151,000 | -$6,766,000 |
| Inv. Purchases | -$4,075,000 | -$36,731,000 | -$140,591,000 | -$58,613,000 |
| Inv. Sales/Matur. | $240,839,000 | $106,021,000 | $55,860,000 | $78,582,000 |
| Other Inv. Act. | -$3,302,000 | -$17,193,000 | $8,120,000 | $5,112,000 |
| Investing Cash Flow | -$136,785,000 | $48,077,000 | -$100,259,000 | $6,038,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $135,000,000 | $0 | $0 | $0 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | -$1,000 | -$50,010,000 | -$1,000 | -$30,007,000 |
| Dividends Paid | -$37,516,000 | -$37,183,000 | -$29,742,000 | -$27,666,000 |
| Other Fin. Act. | -$3,184,000 | -$2,655,000 | -$2,741,000 | -$2,564,000 |
| Financing Cash Flow | $94,299,000 | -$89,848,000 | -$32,484,000 | -$60,237,000 |
| Forex Effect | -$1,548,000 | $1,116,000 | $155,000 | $436,000 |
| Net Chg. in Cash | $38,426,000 | $70,006,000 | $27,023,000 | $8,067,000 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $166,141,000 | $96,135,000 | $69,112,000 | $61,045,000 |
| End Cash | $204,567,000 | $166,141,000 | $96,135,000 | $69,112,000 |
| Free Cash Flow | $74,469,000 | $89,831,000 | $145,113,000 | $49,552,000 |